Primary Hyperoxaluria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer Inc., Zhejiang Tianxin Pharma, Wuxi

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Hyperoxaluria pipeline constitutes 6+ key companies continuously working towards developing 6+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Primary Hyperoxaluria Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years.

*
Primary Hyperoxaluria companies working in the treatment market are Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Primary Hyperoxaluria treatment

*
Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.

*
In July 2025, Arbor Biotechnologies announced that the first patient has been treated in the Phase 1/2 redePHine trial (NCT06839235), evaluating ABO-101, an investigational gene-editing therapy for primary hyperoxaluria type 1 (PH1). The initial dosing took place at the Mayo Clinic. Within the 28-day dose-limiting toxicity observation period, no serious adverse events (AEs) were reported, and the study's safety board has recommended moving forward with additional dosing in the trial.

*
In May 2025, Arbor Biotechnologies, Inc., a biotech firm focused on advancing next-generation genetic therapies, has presented IND- and CTA-supporting data for its lead candidate, ABO-101, targeting primary hyperoxaluria type 1 (PH1), at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans, Louisiana.

*
In February 2025, The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to Arbor Biotechnologies' gene-editing therapy, ABO-101, for the treatment of primary hyperoxaluria type 1 (PH1). These designations provide Arbor with various incentives, including tax credits, waivers of certain regulatory fees, potential market exclusivity, and eligibility for a pediatric priority review voucher if the therapy gains FDA approval.

Primary Hyperoxaluria Overview

Primary Hyperoxaluria is a rare genetic disorder characterized by the overproduction of oxalate, a substance that is normally eliminated through the kidneys in the urine. In individuals with Primary Hyperoxaluria, there is a defect in the liver enzymes responsible for breaking down glyoxylate, leading to an accumulation of oxalate in the body.

Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment

https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight [https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

*
CHK-336: Chinook Therapeutics

*
BBP-711: Cantero Therapeutics

*
BMN 255: BioMarin Pharmaceutical, Inc

*
Oxabact: OxThera

*
Nedosiran: Dicerna Pharmaceuticals, Inc.

Primary Hyperoxaluria Route of Administration

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

*
Molecule Type

Primary Hyperoxaluria Molecule Type

Primary Hyperoxaluria Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Primary Hyperoxaluria Pipeline Therapeutics Assessment

*
Primary Hyperoxaluria Assessment by Product Type

*
Primary Hyperoxaluria By Stage and Product Type

*
Primary Hyperoxaluria Assessment by Route of Administration

*
Primary Hyperoxaluria By Stage and Route of Administration

*
Primary Hyperoxaluria Assessment by Molecule Type

*
Primary Hyperoxaluria by Stage and Molecule Type

DelveInsight's Primary Hyperoxaluria Report covers around 6+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies [https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Primary Hyperoxaluria are - Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutical Co., Wuxi Further Pharmaceutical Co Ltd, Tecoland Corporation, Takeda Pharmaceuticals Company Limited, Intellia Therapeutics, Inc., and others.

Primary Hyperoxaluria Pipeline Analysis:

The Primary Hyperoxaluria pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.

*
Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Hyperoxaluria drugs and therapies [https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Primary Hyperoxaluria Pipeline Market Drivers

*
Rising Prevalence of Primary hyperoxaluria, increasing demand of disease specific novel treatment are some of the important factors that are fueling the Primary Hyperoxaluria Market.

Primary Hyperoxaluria Pipeline Market Barriers

*
However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.

Scope of Primary Hyperoxaluria Pipeline Drug Insight

*
Coverage: Global

*
Key Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others

*
Key Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others

*
Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies

*
Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers

Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Primary Hyperoxaluria Report Introduction

2. Primary Hyperoxaluria Executive Summary

3. Primary Hyperoxaluria Overview

4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Primary Hyperoxaluria Pipeline Therapeutics

6. Primary Hyperoxaluria Late Stage Products (Phase II/III)

7. Primary Hyperoxaluria Mid Stage Products (Phase II)

8. Primary Hyperoxaluria Early Stage Products (Phase I)

9. Primary Hyperoxaluria Preclinical Stage Products

10. Primary Hyperoxaluria Therapeutics Assessment

11. Primary Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Hyperoxaluria Key Companies

14. Primary Hyperoxaluria Key Products

15. Primary Hyperoxaluria Unmet Needs

16 . Primary Hyperoxaluria Market Drivers and Barriers

17. Primary Hyperoxaluria Future Perspectives and Conclusion

18. Primary Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-hyperoxaluria-pipeline-2025-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-alnylam-pharma-genentech-dicerna-pharma-pfizer-inc-zhejiang-tianxin-pharma-wuxi]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.